MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.transci.2017.07.020

Медицинская библиотека · Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2017

Safety and feasibility of therapeutic platelet depletion with Spectra Optia in a pregnant woman.

Małachowski Roman, Grzybowska-Izydorczyk Olga, Besson Nelly, Szmigielska-Kapłon Anna, Nowicki Mateusz, Wierzbowska Agnieszka

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Thrombocytapheresis is an alternative treatment beneficial in rare circumstances, when cytoreductive agents are contraindicated, drug therapy gave no response or the expected response would be too slow. Here we present a case of a pregnant woman who underwent 5 thrombocytaphereses using Spectra Optia device to reduce circulating platelets (PLT) count and prepare for Cesarian section.

PATIENT CHARACTERISTICS AND PERFORMED TREATMENT: A 39-year-old woman with diagnosed chronic myeloid leukemia (CML) was treated with interferon because of too high PLT count. The treatment was well tolerated but the effect was not satisfactory (PLT count remained high). Because of high risk of bleeding during childbirth, the healthcare providers decided to perform thrombocytapheresis to reduce circulating PLT count below 1000×10E3/μl, and to prepare the patient for a planned Cesarean section. The results are presented as mean±SD.

RESULTS

Five therapeutic aphereses procedures were performed, with a Spectra Optia device (TerumoBCT). A mean of 1.3±0.3 total blood volume was processed and we observed a mean PLT drop of 42.3±17.7%. Each apheresis procedure resulted in a PLT level ≤1000×10E3/μl. PLT CE1 was high 50.6±2.6% and reproducible. The white blood cell (WBC) loss was low (18.5%±11.0%). No adverse effects were observed.

CONCLUSION

Therapeutic platelet depletion using the Spectra Optia™ Apheresis System can be effective and safe during pregnancy. Thrombocytapheresis procedures were reproducible and Spectra Optia system successfully adjusted settings to each procedure conditions. Thrombocytapheresis seems to be a viable and safe option even in pregnant women.

Для цитирования: Małachowski Roman, Grzybowska-Izydorczyk Olga, Besson Nelly, Szmigielska-Kapłon Anna, Nowicki Mateusz, Wierzbowska Agnieszka. Safety and feasibility of therapeutic platelet depletion with Spectra Optia in a pregnant woman.. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 2017. DOI: 10.1016/j.transci.2017.07.020.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.